Structured assessment clinic.
(n=200) | ICU (n=77) | Non-ICU (n=123) | ICU versus non-ICU | |
MRC (median ±IQR) | 2±1 | 3±1 | 2±1 | p=0.026 |
Delta MRC (median ±IQR) | 1±1 | 1±1 | 1±1 | p=0.04 |
6MWT (n=170) | ||||
Distance (m) | 342±169 | 342±305 | 429±306 | p=0.181 |
% predicted (median ±IQR) | 70.4±42.0 | 63.9±54.5 | 70.4±40.8 | |
Resting SpO2 (%) (median ±IQR) | 96.0±2.0 | 96.0±2.0 | 96.0±2.3 | p=0.996 |
Nadir SpO2 (%) (median ±IQR) | 94±4 | 94±4 | 94±4 | p=0.858 |
>4% desaturation | 34 | 12 | 22 | p=0.693 |
Max HR (median ±IQR) | 111±17 | 108±20 | 115±16 | p=0.310 |
D-dimer (0.00–0.55 mg/L) (median ±IQR) | 0.48±1.00 | 0.99±1.00 | 0.46±1.00 | p=0.126 |
Ferritin (30–400 μg/L) (median ±IQR) | 164±234 | 186±234 | 145±216 | p=0.340 |
Lymphocyte (1.2–3.5×109/L) (median ±IQR) | 1.9±1.0 | 2.1±1.0 | 1.8±0.9 | p=0.001 |
C reactive protein (0–4 mg/L) (median ±IQR) | 6.2±2.0 | 6.5±3.0 | 2.0±3.0 | p=0.597 |
Questionnaires | ||||
PHQ9 (median ±IQR) | 3.0±11.0 | 7.0±12 | 8.0±11.3 | p=0.621 |
PHQ9 ≥10 (%) | 32 (16%) | 11 (14.3) | 21 (17.1) | |
GAD7 (median ±IQR) | 4.0±9.5 | 8.0±11.0 | 3.0±6.0 | p=0. 168 |
GAD7 ≥10 (%) | 22 (11%) | 11 (14.3) | 11 (8.9) | |
STOPBANG (median ±IQR) | 3.0±2.0 | 3.0±1.0 | 2.5±1.8 | p=0.682 |
STOPBANG ≥4 (%) | 36 (18.0) | 12 (15.6) | 22 (17.0) | |
RR (95% CI) | ||||
Cardiorespiratory cause of breathlessness | 81 (40.5) | 43 (55.8) | 38 (30.9) | 2.8 (1.5 to 5.1) |
Persistent parenchymal change (%) | 64 (32.0) | 35 (45.5) | 29 (23.6) | 2.7 (1.4 to 4.9) |
PE (%) | 4 (2.0) | 1 (1.3) | 3 (2.4) | 0.5 (0.1 to 5.1) |
Other respiratory (%) | 5 (2.5) | 4 (5.1) | 1 (0.8) | 6.7 (0.7 to 60.1) |
Cardiac (%) | 8 (4.0) | 2 (2.6) | 6 (4.9) | 0.7 (0.2 to 2.6) |
GAD7, generalised anxiety disorder questionnaire 7; HR, heart rate; ICU, intensive care unit; 6MWT, 6 min walk test; PHQ9, patient health questionnaire 9; RR, risk ratio; SpO2, oxygen saturations; STOPBANG, snoring, tiredness, observed apnoeas, high blood pressure, BMI, age, neck circumference and male gender questionnaire.